PANCREATIC DUCTAL ADENOCARCINOMA

This study tests whether adding drugs that block the tumor's ability to hide from the immune system can make standard radiation therapy work better for people with advanced pancreatic cancer. About 60 participants will receive radiation plus an immunotherapy drug, with or without…

This study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two markers on pancreatic cancer cells. The goal is to see if these cells are safe and can shrink tumors in people with advanced pancreatic cancer that has not responded to standard …

This early-stage trial is testing a new combination of chemotherapy drugs and high-dose vitamin C, followed by an infusion of the patient's own stem cells, in people with metastatic pancreatic or breast cancer. The goal is to see if this approach is safe and can overcome drug res…

This expanded access program offers ELI-002 7P, an immunotherapy, to pancreatic cancer patients with specific KRAS or NRAS gene mutations who have had their tumor removed but are at high risk of the cancer coming back. The treatment aims to stimulate the immune system to target a…

This study tests whether giving a specific chemotherapy regimen (NALIRIFOX) along with high-dose radiation and another chemo drug (capecitabine) before surgery can help people with pancreatic cancer that has not spread far. The goal is to shrink the tumor enough to allow successf…

This study is for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It tests a new drug called JPI-547 given together with standard chemotherapy. The goal is to find the best dose and see if the combination is safe and helps shrink tumors. Ab…

This early-phase study tests a new drug called IBI343 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 470 participants will take part in mul…

This study tests a new drug called IBI343 combined with other treatments for people with advanced stomach, gastroesophageal junction, or pancreatic cancers that have a specific protein (CLDN18.2). The goal is to see if the combination is safe and shrinks tumors. About 389 adults …

This study tests two experimental drugs, elironrasib and daraxonrasib, given alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drugs are safe and can shrink or control the cancer. About 534 adults with lung,…

This early-stage trial tests a new medicine, BI 765049, in adults with advanced colorectal, stomach, or pancreatic cancer that cannot be removed by surgery or has spread. The main goal is to find the highest safe dose and best way to give the drug. BI 765049 is designed to help t…

This study tests a new treatment that uses a radioactive substance (lead-212) to target and destroy cancer cells in people with advanced solid tumors like pancreatic, stomach, and ovarian cancer. The treatment is guided by imaging to ensure it reaches the right cells. The goal is…

This study tests a combination of two immune-boosting drugs (odetiglucan and mitazalimab) as a maintenance treatment for people with advanced pancreatic cancer that has not worsened after initial chemotherapy. About 100 adults with unresectable pancreatic cancer will receive the …

This study tests a new drug, ASP5834, in people with advanced solid tumors that have specific changes in the KRAS gene. The goal is to find a safe dose and check for side effects. Some participants with colorectal cancer will also receive another drug, panitumumab. The study is f…

This study is testing several new experimental drugs (RAS(ON) inhibitors) combined with standard chemotherapy or other targeted therapies in people with advanced colorectal or pancreatic cancer that has spread. The goal is to see if these combinations are safe and can shrink tumo…

This early-phase study tests a new drug called GV20-0251 in people with advanced solid tumors (like liver, lung, or skin cancer) that have stopped responding to standard therapies. The main goal is to check the drug's safety in a small group of 10 patients. It is not a cure, but …

This study tests a new drug that delivers radiation directly to cancer cells in people with advanced solid tumors. The drug targets a protein found on cells that help tumors grow. The trial has two parts: first finding a safe dose, then testing if it works alone or with chemother…

This study tests whether using a special surgical glue (Glubran® 2) during pancreas surgery can lower the risk of a common complication: a leak from the connection between the pancreas and intestine. About 194 adults with a soft pancreas who are having surgery to remove a tumor w…

This early-phase study tests a new treatment for people with advanced pancreatic cancer that has spread and has a specific mutation called KRAS G12D. The treatment uses tiny particles called exosomes to deliver a molecule that blocks the mutated gene. The goal is to find the best…

This study tests a new drug called PT886 (Spevatamig) in people with advanced stomach, pancreatic, or bile duct cancers that cannot be removed by surgery or have spread. The trial has two parts: first, finding the safest dose of PT886 alone, then testing it combined with chemothe…

This early-stage study tests an experimental drug called PF-08046050 in adults with advanced solid tumors (like lung, colon, or stomach cancer) that have come back or not improved with standard treatments. The drug is designed to stick to cancer cells and kill them. The main goal…

This early-stage study tests a new radioactive drug, [177Lu]Lu-NNS309, in adults with advanced pancreatic, lung, breast, or colorectal cancers that have worsened after standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrin…

This study tests a new drug called AZD4360 in adults with advanced stomach, gastroesophageal junction, bile duct, or pancreatic cancers that have not responded to prior treatments. The drug targets a protein called CLDN18.2 found on some tumor cells. The main goals are to check s…

This study tests a wearable device that creates electric fields (TTFields) combined with chemotherapy for people with metastatic pancreatic cancer. The goal is to see if adding the device is safe and helps control the disease. About 30 adults will participate, and they will use t…

This study tests whether combining three drugs—daratumumab, nivolumab, and a KRAS vaccine—can shrink or control advanced pancreatic and lung cancers. About 54 adults whose cancer has worsened after standard treatment will receive the combination. The goal is to see if the treatme…

This study tests a new treatment for people with advanced pancreatic cancer that has a specific genetic change (KRAS G12V). The treatment uses the patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The goal is to see if this therapy is safe…

This study tests a new approach for people with advanced pancreatic cancer that cannot be removed by surgery. It combines three treatments: a procedure that uses heat to destroy tumor cells (radiofrequency ablation), standard chemotherapy, and an immunotherapy drug called pembrol…

This study is testing a more thorough surgery called total mesopancreas excision for people with pancreatic head cancer. The goal is to remove more tissue around the tumor to lower the chance of cancer coming back. Researchers will follow 90 patients for 24 months to see if this …

This study tests an experimental drug called ART0380 in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to find a safe dose and see if it works alone or with chemotherapy drugs gemcitabine or irinotecan. About 442 participants will take par…

This study tests a new radioactive drug (177Lu-DFC413) to see if it is safe and how it works in people with advanced solid tumors, including pancreatic, lung, breast, colorectal cancers, and soft tissue sarcoma. About 180 adults will receive the drug, and researchers will monitor…

This early-stage study tests a new treatment using a patient's own immune cells, modified in a lab to recognize and attack cancer cells with a specific KRAS mutation. It is for adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to s…

This early-phase study tests a new drug that delivers radiation directly to cancer cells. It is for people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to other treatments. The main goals are to check safety and find the best dose. A…

This study tests a new experimental drug called mavrostobart (PT199) in people with advanced solid tumors, specifically non-small cell lung cancer and pancreatic cancer. The drug is given alone or combined with other cancer treatments. The goal is to find the safest dose and see …

This early-phase study tests a new drug called CT3001 in people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose of CT3001 alone, then testing it combined wit…

This study tests a new daily pill, VS-7375, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS G12D mutation. The goal is to see if the drug is safe and can shrink tumors when used alone or with other cancer treatments. Ab…

This study tests a new way of giving chemotherapy to people with metastatic pancreatic cancer. Instead of one standard regimen, patients will receive two different chemo combinations (NALIRIFOX and GnP) in alternating months. The goal is to see if this approach helps keep the can…

This study tests a new drug, ASP2138, in 25 adults with a type of pancreatic cancer that can be removed by surgery. The drug helps the immune system target cancer cells that have a specific protein called CLDN18.2. Participants get the drug two weeks before surgery, then standard…

This study tests a new drug called BLU-924 in people with advanced pancreatic, lung, or colorectal cancer that has a specific KRAS mutation. The drug aims to block the mutated protein and slow or shrink the cancer. The trial will check safety, side effects, and how well the drug …

This study tests a new drug called sacituzumab tirumotecan (MK-2870), given alone or with other cancer treatments, for people with advanced colorectal, pancreatic, or biliary tract cancers that have spread or cannot be removed by surgery. The main goals are to check the drug's sa…

This early-stage study tests a new drug called IBI3028 in about 493 adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. It is an open-label study, meaning …

This study tests a drug called tegavivint in children, teens, and young adults whose solid tumors have come back or stopped responding to treatment. The goal is to find the safest dose and see if it can shrink tumors by blocking a key growth signal inside cancer cells. About 147 …

This early-phase study tests a new drug called DR-0202 in people with advanced solid tumors (like breast, lung, or prostate cancer) that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. About 96 participants…

This study tests whether adding a medical glue (Glubran 2) to the surgical connection in the pancreas can prevent a serious complication called pancreatic fistula, which is a leak of digestive fluids. About 100 adults undergoing pancreas removal for cancer will be randomly assign…

This study tests a new drug called AZD0901, alone or with other cancer treatments, in people with advanced solid tumors that have a specific protein called CLDN18.2. The goal is to see if the drug is safe and can shrink tumors. About 224 adults with stomach, pancreatic, or bile d…

This early-phase trial tests a new drug called PTM-101 given alongside standard chemotherapy before surgery for people with pancreatic cancer that is borderline resectable or locally advanced. The goal is to see if the combination is safe and can shrink tumors enough to allow suc…

This study tests whether adding the experimental drug atebimetinib to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will receive either the new combination or standard chemo alone. The goal is t…

This study tests an experimental drug called AZD5863 in people with advanced stomach, esophageal, or pancreatic cancers that have not responded to other treatments. The drug is designed to help the body's immune cells attack cancer cells that have a specific marker (CLDN18.2). Th…

This early-phase study tests a new drug, LY3962673, in people with advanced solid tumors that have a specific KRAS G12D mutation, including pancreatic, lung, and colorectal cancers. The main goals are to check safety and see if the drug shrinks tumors, given alone or with chemoth…

This study tests a software called Lipidica 1.0 that analyzes fats in the blood to help screen for pancreatic cancer. It involves 419 people at high risk due to family history or genetic factors. The goal is to see if the software can accurately tell who has cancer and who does n…

This study tests whether a new imaging agent called [18F]FAPI-74 can find certain cancers as well as or better than the standard PET tracer. About 320 adults with one of 11 cancer types (including pancreatic, liver, ovarian, and lung cancers) will receive both tracers and have th…

This study is testing whether adding simple blood tests and symptom reviews to standard screening can find pancreatic cancer earlier in people with a high genetic risk. About 5,000 participants with certain gene changes will be followed over time. The goal is to catch cancer at a…

This study tests whether an MRI scan can detect tiny liver metastases that standard CT scans miss in people with pancreatic cancer. About 120 adults with newly diagnosed pancreatic cancer will get both a CT and an MRI before treatment. If MRI proves better at finding hidden cance…

This study looks at whether combining special PET and MRI scans with blood tests can detect pancreatic cancer early in people with pancreatic cysts. The goal is to find cancer without needing surgery to remove the cyst. About 25 adults with high-risk pancreatic cysts will be enro…

This study tests a new type of PET/CT scan that uses a special injection to find cancer that has spread to the lining of the abdomen (peritoneal carcinomatosis) in people with colorectal, stomach, ovarian, or pancreatic cancer. About 175 adults with known or suspected spread will…

This study is testing a new blood test that looks for tiny particles called exosomes to find pancreatic cancer early. Researchers will check the test's accuracy in 2,000 people, including those with and without the disease. If successful, it could lead to earlier diagnosis and be…

This study tests a new radioactive tracer called [18F]FPyQCP for PET scans to see if it can better detect several cancers, including colorectal, ovarian, gastric, breast, and pancreatic. About 71 adults with these cancers will receive the tracer and have a PET/CT scan. The goal i…

This study is testing a new type of MRI scan that uses a special contrast agent called hyperpolarized carbon-13 pyruvate. The scan shows how tumors process nutrients, which may help doctors predict whether pancreatic cancer treatments are working better than standard scans. The s…

This study collects information from people with advanced pancreatic cancer that has a specific genetic change called KRAS G12R. Researchers want to see how well different combinations of drugs called MEK inhibitors work and how safe they are. About 80 adults will take part, and …

This early-stage study is testing a new imaging agent called RAD301 in 9 people: healthy volunteers and patients with certain cancers like pancreatic, lung, or ovarian cancer. The goal is to see how the body handles the radiation from RAD301 and whether it is safe. No treatment i…

This study collects blood and tumor tissue from 100 people with pancreatic cancer who are about to receive standard chemotherapy. Researchers will use an artificial intelligence (AI) tool to look for biomarkers—clues in the samples—that might predict which treatment works best fo…

This study is looking at tiny molecules called microRNAs in the blood of people with advanced pancreatic cancer. The goal is to see if these molecules can help doctors diagnose the disease earlier, predict how the cancer will progress, and tell if a treatment is working. Research…

This study is testing a new screening program to find pancreatic cancer early in people at high risk. It includes 100 adults aged 50 to 85 who have new diabetes and a high risk score. Participants will get repeated CT scans reviewed by artificial intelligence and give blood sampl…

This study looks at how pancreatic cancer cells get and use nutrients to grow. Researchers will give a special sugar to 16 patients during surgery to trace the cancer's energy use in the lab. The goal is to find weaknesses in the cancer's fuel system that could lead to new treatm…

This study compares two surgical methods for removing part of the pancreas in adults with certain tumors. One method uses small incisions and a camera (laparoscopic), while the other uses a larger cut (open surgery). The goal is to see which approach leads to fewer complications …

This study follows 20,000 people who have a family history of pancreatic cancer or carry certain gene changes that raise their risk. Researchers will track them over time to learn how to detect pancreatic cancer earlier and possibly prevent it. The goal is to improve survival by …

This study looks at whether genetic information from tumors can help doctors choose better treatments for pancreatic cancer. About 200 adults with early or locally advanced pancreatic cancer will receive standard chemotherapy and provide blood, tissue, and fluid samples for genet…

This study is developing a blood test that looks at tiny genetic particles called microRNAs to predict how well pancreatic cancer will respond to chemotherapy given before surgery. Researchers will collect blood samples from 200 patients with pancreatic cancer who are about to re…

This study enrolls 5,000 people at high risk for pancreatic cancer to donate blood, pancreatic juice, and medical images over 10 years. Researchers will use this information to develop and validate tests that can detect pancreatic cancer earlier, when it may be more treatable. Pa…

This study is for people at high risk of pancreatic cancer due to family history or certain genetic conditions. Researchers will use MRI and endoscopic ultrasound to screen 700 participants regularly, hoping to find cancer earlier when it may be more treatable. The goal is to lea…

This study follows 4,000 adults with pancreatic cysts to learn which ones turn into cancer. Many cysts are harmless, but some may be early signs of pancreatic cancer. By tracking changes over time, researchers hope to find better ways to tell dangerous cysts from safe ones, reduc…

This study is for people with metastatic pancreatic cancer who are starting their first chemotherapy. Researchers want to see if a blood test that measures tumor DNA (ctDNA) can detect whether the cancer is shrinking or growing much earlier than the usual 8-week scan. If successf…